Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1113-1119

  Saldova, R ^a   Reuben, J M ^b   Abd Hamid, U M ^a,c   Rudd, P M ^a   Cristofanilli, M ^b,d  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Biomarker; Breast cancer; Circulating tumor cells; N linked glycans

Indexed keywords

GLYCAN DERIVATIVE; SIALYL LEWIS X ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER CELL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 79551481037     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq570     Document Type: Article

References (35)

1. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
2. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
3. Sieuwerts AM, Kraan J, Bolt J et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009; 101: 61-66.
4. Reuben JM, Lee BN, Li C et al. Genomic of circulating tumor cells in metastatic breast cancer. J Clin Oncol 2007; 25: 1002.
5. Mintz PJ, Kim J, Do KA et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003; 21: 57-63.
6. Hakomori S. Tumor-associated carbohydrate antigens. Annu Rev Immunol 1984; 2: 103-126.
7. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008; 7: 1388-1394.
8. Abd Hamid UM, Royle L, Saldova R et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008; 18: 1105-1118.
9. Kirmiz C, Li B, An HJ et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics 2007; 6: 43-55.
10. Kyselova Z, Mechref Y, Kang P et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem 2008; 54: 1166-1175.
11. Saldova R, Wormald MR, Dwek RA, Rudd PM. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 2008; 25: 219-232.
12. Fry SA, Van den Steen PE, Royle L et al. Cancer-associated glycoforms of gelatinase B exhibit a decreased level of binding to galectin-3. Biochemistry 2006; 45: 15249-15258.
13. Drake PM, Cho W, Li B et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem 2009; 56: 223-236.
14. Riethdorf S, Fritsche H, Muller V et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007; 13: 920-928.
15. Royle L, Radcliffe CM, Dwek RA, Rudd PM. Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol Biol 2006; 347: 125-143.
16. Royle L, Campbell MP, Radcliffe CM et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 2008; 376: 1-12.
17. Guile GR, Rudd PM, Wing DR et al. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem 1996; 240: 210-226.
18. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37: 529-540.
19. Ignatiadis M, Georgoulias V, Mavroudis D. Circulating tumor cells in breast cancer. Curr Opin Obstet Gynecol 2008; 20: 55-60.
20. Ignatiadis M, Kallergi G, Ntoulia M et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008; 14: 2593-2600.
21. Xenidis N, Perraki M, Kafousi M et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006; 24: 3756-3762.
22. Quintela-Fandino M, Lopez JM, Hitt R et al. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol 2006; 24: 3611-3618.
23. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430.
24. Shaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 2023-2029.
25. Moreno JG, Miller MC, Gross S et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005; 65: 713-718.
26. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005; 4: 477-488.
27. Ugorski M, Laskowska A. Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 2002; 49: 303-311.
28. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 2002; 21: 3631-3643.
29. Pinho SS, Matos AJ, Lopes C et al. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression. BMC Cancer 2007; 7: 124.
30. Pierce A, Saldova R, Abd Hamid UM et al. Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients. Glycobiology 2010; 20: 1283-1288.
31. Knezevic A, Polasek O, Gornik O et al. Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res 2009; 8: 694-701.
32. Aubert M, Panicot L, Crotte C et al. Restoration of alpha(1,2) fucosyltransferase activity decreases adhesive and metastatic properties of human pancreatic cancer cells. Cancer Res 2000; 60: 1449-1456.
33. Magnani JL. The discovery, biology, and drug development of sialyl Lea and sialyl Lex. Arch Biochem Biophys 2004; 426: 122-131.
34. Arnold JN, Saldova R, Hamid UM, Rudd PM. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008; 8: 3284-3293.
35. Giordano A, Giuliano M, Handy BC et al. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): correlation with immunohistochemically defined molecular subtypes and metastatic disease sites. J Clin Oncol 2010; 28 (15 Suppl): 115s (Abstr 1000).